An Educational Intervention to Improve Adverse Drug Reactions Reporting Among Healthcare Practitioners in Selected Pediatric Hospitals in Iraq

Bootan A. Salih ^1,*, Omer Q. Allela ², Raad A Kaskoos ³, Javed Ahamad ⁴

The main goal of the study is to design an intervention program to increase knowledge attitude and practice of healthcare practitioners towards pharmacovigilance.

Abstract

Background: Pharmacovigilance is getting a lot of attention lately because it plays a crucial role in managing effective medication use in clinical settings. The main goals of pharmacovigilance are to protect and enhance public health and reduce the harm caused by drugs by ensuring their justified use. This study aimed to create a pharmacovigilance education program, record adverse medication reactions, and assess the impact of the program on the knowledge, attitudes, and practices (KAP) of healthcare professionals in several Iraqi pediatric hospitals. In a three-phase study, healthcare professionals were asked to complete a KAP questionnaire before and after the educational program. Results: The educational program significantly improved participants' knowledge about adverse drug reactions (ADRs) and pharmacovigilance (PV). Similar improvements were observed in attitudes and practices. Conclusion: Ongoing education programs are essential to assess their impact on achieving and maintaining the desired outcomes of the ADR reporting system and enhancing inter-professional practices.

Keywords: Adverse Drug Reaction reporting, educational program, healthcare practitioners, KAP questionnaire and Iraq.

References

Abdel- Latif MM, Abdel- Wahab BA. Knowledge and awareness of adverse drug reactions and pharmacovigilance practices among healthcare professionals in Al-Madinah Al-Munawwarah, Kingdom of Saudi Arabia. Saudi Pharm J. 2015;23(2):154– 161.

Abu Farha R, Abu Hammour K, Rizik M, Aljanabi R, Alsakran L. Effect of educational intervention on healthcare providers knowledge and perception towards pharmacovigilance: a tertiary teaching hospital experience. Saudi Pharm J. 2018;26(5):611– 616.

Abu Hammour K, El-Dahiyat F, Abu Farha R. Health care professionals’ knowledge and perception of pharmacovigilance in a tertiary care teaching hospital in Amman, Jordan J. Evaluat. Clin. Pract., 23 (2017), pp. 608-613.

Adisa R, Omitogun TI. Awareness, knowledge, attitude and practice of adverse drug reaction reporting among health workers and patients in selected primary healthcare centres in Ibadan, southwestern Nigeria. BMC Health Serv Res. 2019;19(1):14.

Allen, H.C., Garbe, M.C., Lees, J., Aziz, N., Chaaban, H., Miller, J.L., Johnson, P., DeLeon, S. (2018). Off-Label Medication use in Children, More Common than We Think: A Systematic Review of the Literature. J. Okla. State Med. Assoc. 111: 776–783.

Almandil NB. Healthcare professionals’ awareness and knowledge of adverse drug reactions and pharmacovigilance. Saudi Med J. 2016;37(12):1350– 1355.

Alraie NA, Saad AA, Sabry NA, Farid SF. Adverse drug reactions reporting: a questionnaire- based study on Egyptian pharmacists’ attitudes following an awareness workshop. J Eval Clin Pract. 2016;22(3):349– 355.

Alshakka M, Bassalim H, Alsakkaf K, et al. Knowledge and perception towards pharmacovigilance among healthcare professionals in tertiary care teaching hospital in Aden, Yemen. J Pharm Pract Community Med. 2016;2(1):21– 28.

Al-Shammari TM, Almoslem MJ. Knowledge, attitudes & practices of healthcare professionals in hospitals towards the reporting of adverse drug reactions in Saudi Arabia: a multi- centre cross sectional study. Saudi Pharm J. 2018;26(7):925– 931.

Bogolubova S, Padayachee N, Schellack N. Knowledge, attitudes and practices of nurses and pharmacists towards adverse drug reaction reporting in the South African private hospital sector. Heal SA Gesondheid. 2018;23:1– 9.

Choonara I., Conroy S. Unlicensed and off-label drug use in children: Implications for safety. Drug Saf. 2002;25:1–5.

Cuzzolin L., Atzei A., Fanos V. Off-label and unlicensed prescribing for newborns and children in different settings: A review of the literature and a consideration about drug safety. Expert Opin. Drug Saf. 2006;5:703–718.

Dittrich, A. T. M., Draaisma, J. M. T., van Puijenbroek, E. P., and Loo, D. M. W. M. T. (2020). Analysis of Reporting Adverse Drug Reactions in Paediatric Patients in a university Hospital in the Netherlands. Paediatr. Drugs 22 (4), 425–432. doi:10.1007/s40272-020-00405-3.

Ergun Y, Ergun TB, Toker E, et al. Knowledge attitude and practice of Turkish health professionals towards pharmacovigilance in a university hospital. Int Health. 2019;11(3):177– 184.

Gupta S, Nayak R, Shivaranjani R, Vidyarthi S. A questionnaire study on the knowledge, attitude, and the practice of pharmacovigilance among the healthcare professionals in a teaching hospital in South India. Perspect Clin Res. 2015; 6(1): 45.

Haines HM, Meyer JC. Knowledge, attitudes and practices of health care professionals towards adverse drug reaction reporting in public sector primary health care facilities in a South African district. Eur J Clin Pharmacol. 2020;76:991– 1001.

Hussain R, Hassali MA, Ur Rehman A, et al. Physicians’ understanding and practices of pharmacovigilance: qualitative experience from a lower middle- income country. Int J Environ Res Public Health. 2020;17(7):15.

Laven A, Schmitz K, Franzen WH. Reporting adverse drug reactions: contribution, knowledge and perception of German pharmacy professionals. Int J Clin Pharm. 2018;40(4):842– 851.

Le TT, Thanh T, Nguyen H, et al. Factors associated with spontaneous adverse drug reaction reporting among healthcare professionals in Vietnam. J Clin Pharm Ther. 2020;45:122– 127.

Maigetter K, Pollock AM, Kadam A, Ward K, Weiss MG. Pharmacovigilance in India, Uganda and South Africa with reference to WHO’s minimum requirements. Int J Heal Policy Manag. 2015;4(5):295– 305.

Mason J., Pirmohamed M., Nunn T. Off-label and unlicensed medicine use and adverse drug reactions in children: A narrative review of the literature. Eur. J. Clin. Pharmacol. 2011;68:21–28.

Najafi S. Importance of pharmacovigilance and the role of healthcare professionals. J Pharmacovigil. 2018;06(01):1– 2.

Molokhia M, Tanna S, Bell D. Improving reporting of adverse drug reactions: systematic review. Clin Epidemiol. 2009;1:75– 92.

Nisa ZU, Zafar A, Sher F. Assessment of knowledge, attitude and practice of adverse drug reaction reporting among healthcare professionals in secondary and tertiary hospitals in the capital of Pakistan. Saudi Pharm J. 2018; 26(4): 453–461.

Rohilla A, Singh N. Pharmacovigilance: needs and objectives. J Adv Pharm Educ Res. 2012;2(4):201– 205.

Sahu RK, Yadav R, Prasad P, Roy A, Chandrakar S. Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance. Springerplus. 2014;3(1):1– 9.

Sartori D, Aronson JK, Onakpoya IJ. Signals of adverse drug reactions communicated by pharmacovigilance stakeholders: Protocol for a scoping review of the global literature. Syst Rev. 2020;9(1):1– 9.

Selvan, N., Saravanan, R., & M., S. (2016). Effect of educational interventions on pharmacovigilance awareness among M.B.B.S. internee’s in a tertiary care teaching hospital. International Journal of Basic & Clinical Pharmacology, 5(1), 149–154.

Suyagh M, Farah D, Abu Farha R. Pharmacist’s knowledge, practice and attitudes toward pharmacovigilance and adverse drug reactions reporting process. Saudi Pharm J. 2015;23(2):147– 153.

Upadhyaya HB, Vora MB, Nagar JG, Patel PB. Knowledge, attitude and practices toward pharmacovigilance and adverse drug reactions in postgraduate students of Tertiary Care Hospital in Gujarat. J Adv Pharm Technol Res. 2015;6(1):29– 34.

Van Hunsel F, Gardarsdottir H, de Boer A, Kant A. Measuring the impact of pharmacovigilance activities, challenging but important. Br J Clin Pharmacol. 2019;85(10):2235– 2237.

Varallo FR, Planeta CS, Mastroianni PD. Effectiveness of pharmacovigilance: multifaceted educational intervention related to the knowledge, skills and attitudes of multidisciplinary hospital staff. Clinics. 2017;72(1):51– 57.

World Health Organization. Pharmacovigilance. https://www.who.int/ medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/ [2018; Accessed October 24, 2018.]

WHO. Joining the WHO Programme for International Drug Monitoring. World Heal Organ. 2010:1- 2. https://www.who.int/ medicines/areas/quality_safet y/safety_efficacy/Joining_the_WHO_Programme.pdf?ua=1. Accessed 12 Jul 2021.

WHO. The Safety of Medicines in Public health programmes: pharmacovigilance an essential tool. WHO Libr Cat Data. 2006:61. http://www.who.int/medic ines/areas/ quali ty_safet y/safety_effic acy/Pharm acovi gilan ce_B.pdf. Accessed 20 Jun 2021.